Genmab

2 508 DKK +0,68 %

1 sijoittaja seuraa yhtiötä

www.genmab.com/investors

Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.

Liikevaihto

14,6 mrd.

EBIT %

43,56 %

P/E -luku

29,7

Osinkotuotto %

Tavoitehinta

Suositus

Päivitetty

NASDAQ Copenhagen

GMAB

Päivän matalin / päivän korkein hinta

2 502 / 2 538 DKK

Markkina-arvo

165,7 mrd. DKK

Vaihto

215,97 milj. DKK

Vaihtomäärä, kappaletta

86 t.

Pörssikalenteri

Osavuosikatsaus

07.11.2023

Näytä Kaikki sisältötyypit

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Pörssitiedote28.09.2023

Genmab

Pörssikalenteri

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab Announces Financial Results for the First Half of 2023

Genmab Updates 2023 Financial Guidance

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023

Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress